vimarsana.com

Latest Breaking News On - Esperion therapeutics inc - Page 12 : vimarsana.com

4 Tips to Get High Cholesterol Under Control

(Family Features) Heart disease is the nation’s leading cause of death for men and women, according to the Centers for Disease Control and Prevention, but many people aren’t aware they

Esperion Therapeutics, Inc (NASDAQ:ESPR) Given Consensus Rating of Hold by Analysts

Shares of Esperion Therapeutics, Inc. (NASDAQ:ESPR – Get Free Report) have received an average recommendation of “Hold” from the seven analysts that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold recommendation and three have issued a buy recommendation on the company. The average 1 year price objective […]

Esperion Therapeutics, Inc (NASDAQ:ESPR) Forecasted to Post Q1 2024 Earnings of ($0 25) Per Share

Esperion Therapeutics, Inc. (NASDAQ:ESPR – Free Report) – Investment analysts at Northland Capmk issued their Q1 2024 earnings per share (EPS) estimates for shares of Esperion Therapeutics in a research note issued on Wednesday, February 28th. Northland Capmk analyst C. Byrnes forecasts that the biopharmaceutical company will post earnings per share of ($0.25) for the […]

Esperion Therapeutics (NASDAQ:ESPR) Releases Earnings Results, Beats Estimates By $0 03 EPS

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03, MarketWatch Earnings reports. The company had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the […]

Esperion Therapeutics (NASDAQ:ESPR) Releases Earnings Results, Beats Estimates By $0 03 EPS

Esperion Therapeutics (NASDAQ:ESPR – Get Free Report) released its earnings results on Tuesday. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.53) by $0.03, MarketWatch Earnings reports. The company had revenue of $32.25 million during the quarter, compared to analysts’ expectations of $26.84 million. During the […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.